<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00775762</url>
  </required_header>
  <id_info>
    <org_study_id>2008-004626-17</org_study_id>
    <nct_id>NCT00775762</nct_id>
  </id_info>
  <brief_title>Anti-Inflammatory and Anti-Platelet Effect of Clopidogrel and Aspirin vs Aspirin Alone in Symptomatic Polyvascular Disease and in Patients With Multiple Recurrent Cardiovascular Events</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a monocentric, randomized, opened study to assess the anti-inflammatory and
      anti-platelet effect of Clopidogrel and aspirin versus aspirin or clopidogrel alone in
      patients with symptomatic polyvascular disease and with multiple recurrent cardiovascular
      events.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The aim of the present study is to demonstrate the superior antinflammatory effect of Clopidogrel and Aspirin vs Aspirin or Clopidogrel alone in term of levels of selected circulating inflammatory markers</measure>
    <time_frame>three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The aim of the present study is to demonstrate the superior antiplatelet effect of Clopidogrel and Aspirin vs Aspirin or Clopidogrel alone in term of TXA2 serum levels</measure>
    <time_frame>three months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">213</enrollment>
  <condition>Polyvascular Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>clopidogrel plus aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>Aspirin (75-100 mg)die for three months</description>
    <arm_group_label>aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Clopidogrel (75mg) die for three months</description>
    <arm_group_label>clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel plus aspirin</intervention_name>
    <description>clopidogrel 75 mg die plus aspirin 75-100 mg for three months</description>
    <arm_group_label>clopidogrel plus aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symptomatic polyvascular disease or recurrent cardiovascular events. In
             particular patients with established stable coronary artery disease associated with
             peripheral disease or cerebrovascular disease and patients with more than two acute
             cardiovascular events.

        Exclusion Criteria:

          -  chronic treatment with anticoagulant drugs and the use of other antiplatelet therapy;

          -  intolerance/allergy to Aspirin or to Clopidogrel

          -  platelet counts outside the range of 125-450 10^9/l

          -  inflammatory or infectious disease

          -  malignancies or immunologic or hematological disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luigi M Biasucci, MD</last_name>
    <email>lmbiasucci@virgilio.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Catholic University of the Sacred Heart, Department of Cardiovascular Medicine</name>
      <address>
        <city>Rome</city>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luigi M Biasucci, MD</last_name>
      <email>lmbiasucci@virgilio.it</email>
    </contact>
    <investigator>
      <last_name>Luigi M Biasucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2008</study_first_submitted>
  <study_first_submitted_qc>October 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2008</study_first_posted>
  <last_update_submitted>October 17, 2008</last_update_submitted>
  <last_update_submitted_qc>October 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Luigi Marzio Biasucci</name_title>
    <organization>Catholic University of the Sacred Heart</organization>
  </responsible_party>
  <keyword>Symptomatic Polyvascular disease</keyword>
  <keyword>Multiple recurrent cardiovascular events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

